Kalvista Pharmaceuticals, Ltd.
Clinical trials sponsored by Kalvista Pharmaceuticals, Ltd., explained in plain language.
A pharmaceutical company developing oral therapies for hereditary angioedema and other diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Teens with rare swelling disorder get new drug tested
Disease control CompletedThis study looked at how a new oral medication (sebetralstat) works in the bodies of 11 teenagers aged 12 to 17 with hereditary angioedema (HAE) types I or II. The goal was to measure drug levels and timing in the blood. All participants were already in a larger HAE trial. The st…
Phase: PHASE3 • Sponsor: KalVista Pharmaceuticals, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New pill shows promise for controlling rare swelling disorder
Disease control CompletedThis study looked at the long-term safety of an oral medication called KVD900 for treating swelling attacks in people with hereditary angioedema (HAE) types I or II. The trial enrolled 145 adolescents and adults who had already completed a previous study. Participants took KVD900…
Phase: PHASE3 • Sponsor: KalVista Pharmaceuticals, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for kids with rare swelling disorder: sebetralstat shows promise
Symptom relief CompletedThis study tested a drug called sebetralstat in 36 children aged 2 to 11 with hereditary angioedema (HAE) types I or II, a condition that causes sudden, painful swelling. The goal was to see if the drug is safe and how well it works to relieve attacks. The trial was open-label, m…
Phase: PHASE3 • Sponsor: KalVista Pharmaceuticals, Ltd. • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
Real-World data on HAE attack treatment collected in completed study
Knowledge-focused CompletedThis study followed 88 people with hereditary angioedema (HAE) types I or II who already use icatibant for sudden attacks. Participants filled out diaries for 48 hours after each attack to report symptom changes, severity, and anxiety levels. The goal was to gather real-world inf…
Sponsor: KalVista Pharmaceuticals, Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC